BASi has entered into a Preferred Provider Agreement with G1 Therapeutics for preclinical services, including toxicology, bioanalytical and analytical testing, to support G1’s drug development programs. G1 is a privately held company that develops small molecule therapeutics to protect bone marrow from damage due to chemotherapy or radiation.   BASi’s president, chief executive officer, and chief financial officer, Jacqueline M. Lemke, said, “With our common focus on innovation and scienti...